| Title |
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE−/− Mice
|
|---|---|
| Published in |
Molecular Medicine, February 2015
|
| DOI | 10.2119/molmed.2014.00195 |
| Pubmed ID | |
| Authors |
Kai Meng, Qiutang Zeng, Qinghua Lu, Yingzhong Lin, Bangwei Wu, Kunwu Yu, Zhaoqiang Dong, Jianwei Zhang, Meng Chai, Yuyang Liu, Qingwei Ji, Yujie Zhou |
| Abstract |
Valsartan has a protective effect against hypertension and atherosclerosis in humans and experimental animal models. This study aimed to determine the effect of prolonged treatment with angiotensin II (Ang II) on atherosclerosis and the effect of valsartan on the activity of CD4(+) T lymphocyte subsets. The results showed that prolonged treatment (8 wks) with exogenous Ang II resulted in an increased atherosclerotic plaque size and a switch of stable-to-unstable plaque via modulating on CD4(+) T lymphocyte activity, including an increase in the T helper cell type 1 (Th1) and Th17 cells and a decrease in Th2 and regulatory T (Treg) cells. In contrast, valsartan treatment efficiently reversed the imbalance in CD4(+) T lymphocyte activity, ameliorated atherosclerosis and elicited a stable plaque phenotype in addition to controlling blood pressure. In addition, treatment with anti-interleukin (IL)-5 monoclonal antibodies weakened the antiatherosclerotic effects of valsartan without affecting blood pressure. |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 20% |
| Student > Doctoral Student | 1 | 10% |
| Student > Ph. D. Student | 1 | 10% |
| Student > Master | 1 | 10% |
| Researcher | 1 | 10% |
| Other | 1 | 10% |
| Unknown | 3 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 50% |
| Biochemistry, Genetics and Molecular Biology | 1 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 10% |
| Unknown | 3 | 30% |